<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391443</url>
  </required_header>
  <id_info>
    <org_study_id>AC-052-321</org_study_id>
    <nct_id>NCT00391443</nct_id>
  </id_info>
  <brief_title>BUILD 3: Bosentan Use in Interstitial Lung Disease</brief_title>
  <acronym>BUILD 3</acronym>
  <official_title>Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group,
      placebo-controlled, event-driven, group sequential, phase III superiority study. The primary
      objective is to demonstrate that bosentan delays disease worsening or death in patients with
      Idiopathic Pulmonary Fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Occurrence of Disease Worsening or Death up to End of Study.</measure>
    <time_frame>36 months</time_frame>
    <description>Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.</measure>
    <time_frame>12 months</time_frame>
    <description>Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">616</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight &gt; 40 kg) or bosentan 62.5 mg b.i.d. (if body weight &lt; 40 kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive placebo matching the bosentan treatment regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight &gt; 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight &lt; 40 kg)</description>
    <arm_group_label>Bosentan</arm_group_label>
    <other_name>Ro 47-0203</other_name>
    <other_name>ACT-050088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching bosentan 62.5 mg tablets and 125 mg tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Male or female aged 18 years or older (females of child-bearing potential must have
             been surgically sterilized or use a reliable method of contraception.)

          -  Proven diagnosis of IPF according to American Thoracic Society / European Respiratory
             Society (ATS-ERS) statement, of &lt;3 years, with surgical lung biopsy (SLB)

        Exclusion Criteria:

          -  Interstitial lung disease due to conditions other than IPF.

          -  Presence of extensive honeycombing (HC) on baseline high-resolution computed
             tomography (HRCT) scan.

          -  Severe concomitant illness limiting life expectancy (&lt;1 year).

          -  Severe restrictive lung disease.

          -  Obstructive lung disease.

          -  Diffusing capacity of the lung for carbon monoxide &lt;30% predicted.

          -  Residual volume &gt; or = 120% predicted.

          -  Documented sustained improvement of patient's IPF condition up to 12 months prior to
             randomization with or without IPF-specific therapy.

          -  Recent pulmonary or upper respiratory tract infection (up to 4 weeks prior to
             randomization).

          -  Acute or chronic impairment (other than dyspnea) limiting the ability to comply with
             study requirements.

          -  Chronic heart failure with New York Heart Association (NYHA) class III/IV or known
             left ventricular ejection fraction &lt;25%.

          -  Alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) &gt; 1.5
             times the upper limit of the normal ranges.

          -  Moderate to severe hepatic impairment.

          -  Serum creatinine &gt; or = 2.5 mg/dl or chronic dialysis.

          -  Hemoglobin concentration &lt;75% the lower limit of the normal ranges.

          -  Systolic blood pressure &lt;85 mmHg.

          -  Pregnancy or breast-feeding.

          -  Current drug or alcohol dependence.

          -  Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of
             randomization):oral corticosteroids (&gt;20 mg/day of prednisone or equivalent),
             immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of
             N-acetylcysteine (prescribed for IPF).

          -  Oral anticoagulants other than those indicated for a venous or arterial thrombotic
             disease.

          -  Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A,
             tacrolimus) up to 1 week prior to randomization.

          -  Treatment with an endothelin receptor antagonist up to 3 months prior to
             randomization.

          -  Participation in the BUILD 1 trial.

          -  Treatment with another investigational drug up to 3 months prior to randomization or
             planned treatment.

          -  Known hypersensitivity to bosentan or any of the excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Leconte</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Division of Pulmonary</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC University Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Division of Pulmonary &amp; Critical Care</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis University of California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF-Interstitial Lung Disease Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Medicine-Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical &amp; Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine-Dept of Internal Med-Pulmonary &amp; Critical Care</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago - Section of Pulmonary, Dept of Medicine, Respiratory Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Pulmonary Medicine</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita Clinic, P.A.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Group, Cardio-Pulmonary Research</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Allergy Associates, P.A.</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital - Pulmonary Department</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center - IPF Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern Dallas-Div. of Pulm &amp; Critical Care Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia - Div. of Pulmonary &amp; Critical Care</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-3240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Public Hospital, Lung Transplantation &amp; Respiratory Medicine</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital - Lung Transplant, Thoraic Dept.</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital-Respiratory Clinical Trials Unit</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital; Advanced Lung Disease Unit</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz-Klinische Abteilung für Pulmonologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Thermenregion Hochegg</name>
      <address>
        <city>Grimmenstein</city>
        <zip>2840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck-Div. of Clinical &amp; Internal Medicine</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna and AKH-Div of Pulmonology</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Wagner Spital Wien</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter C. Mackenzie Health Sciences Centre-Univeristy of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Health Care Corporation of St. John's-Eastern Health</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital-Rosedale Medical Center PFT Lab</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4X 1W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre Dame - Centre Hospitalier de L'Universit de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie et de Pneumologie de l'Universite Laval</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital for Lung Disease &quot;Jordanovac&quot;</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc - Dept of Respiratory Disease-IP Pavlova</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayer Faculty Hospital Prague-Dept of Respiratory Disease</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Na Bulovce</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HYLAB, Clinique du Mail</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille-Hopital Albert Calmette</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring</name>
      <address>
        <city>Berlin</city>
        <zip>D-14165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Coswig; Centre for Pulmonology and Thoracic Surgery</name>
      <address>
        <city>Coswig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Donaustauf-Zentrum für Pneumologie</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik, Pneumologie/Allergologie</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik, Abteilung Pneumologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universitat Giessen-Zentrum für Innere Medizin</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg GmbH</name>
      <address>
        <city>Heidelberg</city>
        <zip>01640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik fur Lungenerkrankungen</name>
      <address>
        <city>Immenhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein GmbH-Medizinische Klinik 1 Pneumologie-Kardiologie</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München Medizinische Klinik und Poliklinik 1 - Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misicordiae Hospital</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Centre-Div. for Pulmonary Disease</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization: Ein Karem-Institute of Pulmonology</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Istitute-Rabin Medical Centre: Beilinson Campus</name>
      <address>
        <city>Petach Tikvah</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Centre-Pulmoary Istitute</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Centre-Institute of Pulmonary &amp; Allergic Diseases</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Centre</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Forli-Presidio Ospedaliero Stabilimento</name>
      <address>
        <city>Forli</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe Milanocuore, Unita Operativa di Pneumologia</name>
      <address>
        <city>Milan</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano (Torino)</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova - Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologia ISMETT</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University degli Studi Siena, Policlinico le Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tosei General Hospital</name>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Himeji medical center</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <zip>670-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular Respiratory Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenri Hospital</name>
      <address>
        <city>Tenri</city>
        <state>Nara</state>
        <zip>632-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki - Chuo Chest Medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gil Medical Centre, Gachon University</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Centre</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoonChunHyang University Bucheon Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za Plucne bolest l TBC Klinickog Centra Srbije</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za Plucne bolesti Vojvodine, Sremska Kamenica</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron-Neumologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona (Pneumology Service)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel-Div of Pneumology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern-Div of Pulmonary Medicine</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hopital Zurich-Clinic for Pneumology &amp; Lung Transplant Program</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NWLC, Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Former Serbia and Montenegro</country>
    <country>Slovakia</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2006</study_first_submitted>
  <study_first_submitted_qc>October 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2006</study_first_posted>
  <results_first_submitted>April 25, 2012</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2012</results_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>September 9, 2015</last_update_submitted>
  <last_update_submitted_qc>September 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BUILD 3</keyword>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Tracleer</keyword>
  <keyword>Interstitial Lung Disease</keyword>
  <keyword>bosentan</keyword>
  <keyword>Actelion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
        </group>
        <group group_id="P2">
          <title>Bosentan</title>
          <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209">1 patient in the bosentan arm did not receive treatment &amp; was excluded from the Safety Population.</participants>
                <participants group_id="P2" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
        </group>
        <group group_id="B2">
          <title>Bosentan</title>
          <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="209"/>
            <count group_id="B2" value="407"/>
            <count group_id="B3" value="616"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="9.1"/>
                    <measurement group_id="B2" value="63.8" spread="8.4"/>
                    <measurement group_id="B3" value="63.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 41 and 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 61 and 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Occurrence of Disease Worsening or Death up to End of Study.</title>
        <description>Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).</description>
        <time_frame>36 months</time_frame>
        <population>The primary analysis was performed on the Intent To Treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
            <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Disease Worsening or Death up to End of Study.</title>
          <description>Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).</description>
          <population>The primary analysis was performed on the Intent To Treat (ITT) population.</population>
          <units>participants with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>month 4 (122 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 8 (244 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month12 (366 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 18 (549 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 24 (732 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 30 (915 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 36 (1098 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2110</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.850</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.658</ci_lower_limit>
            <ci_upper_limit>1.097</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.</title>
        <description>Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).</description>
        <time_frame>12 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
            <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year.</title>
          <description>Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).</description>
          <population>ITT population</population>
          <units>percentage of participants with event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="18.3" upper_limit="30.3"/>
                    <measurement group_id="O2" value="19.9" lower_limit="16.1" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2542</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative risk reduction</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All treatment-emergent adverse events occurring after the start of study treatment and within 24 hours after the end of study treatment</time_frame>
      <desc>One subject who did not receive study treatment (bosentan) was excluded from the safety population. Events listed as idiopathic pulmonary fibrosis were reported as worsening of idiopathic pulmonary fibrosis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
        </group>
        <group group_id="E2">
          <title>Bosentan</title>
          <description>Initial dose: 62.5 mg twice daily (b.i.d.) for 4 weeks. Target dose: - body weight &gt; 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated); - body weight &lt; 40 kg (90 lb): 62.5 mg b.i.d.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>VENTRICULAR HYPOKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>MENIERE'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DYSKINESIA OESOPHAGEAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>MESENTERIC ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OTICUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>VIRAL LABYRINTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PULMONARY FUNCTION TEST DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>SJOGREN'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>FRACTURE NONUNION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PANIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PROSTATISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>IDIOPATHIC PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ACUTE INTERSTITIAL PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>TRANSURETHRAL PROSTATECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LUNG TRANSPLANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>TEMPORAL ARTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="386" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>IDIOPATHIC PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="406"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="406"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Actelion, with steering committee, shall complete the review and provide any modifications required to protect Actelion's patent rights and confidential information within sixty (60) days of receipt of the proposed publication. During this period, Investigator shall not permit publication. If Actelion reasonably anticipates filing a patent application claiming an invention arising out of the Study, such publication shall be delayed until after the application is filed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Isabelle Leconte,PhD -Data Science Group Leader, Director</name_or_title>
      <organization>Actelion Pharmaceuticals Ltd</organization>
      <phone>+41 61 565 64 18</phone>
      <email>isabelle.leconte@actelion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

